相关实验视频

Updated: Jan 6, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

PRMT1作为多发性骨髓瘤中关键生存依赖性点的治疗潜力

Tabish Hussain¹, Sharad Awasthi¹, Farid Shahid^1,2

¹Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, 1901 East Rd, Houston, TX, 77054, USA.

|November 4, 2025

概括

多发性髓瘤细胞依赖蛋白质氨酸N-甲基转移酶1 (PRMT1) 才能生存. 用GSK3368715抑制PRMT1会减少细胞生长并影响DNA损伤反应,为这种血液性恶性瘤提供潜在的新疗法.

科学领域:

血液学的恶性瘤
癌症生物学癌症生物学
分子瘤学分子瘤学

背景情况:

多发性骨髓瘤 (MM) 是一种流行的血液性恶性瘤,由于药物耐药性和复发,在治疗中存在重大挑战.
确定新的治疗点对于改善MM治疗结果至关重要.
蛋白质氨酸N-甲基转移酶1 (PRMT1) 已经成为MM细胞的潜在漏洞.

研究的目的:

研究PRMT1在MM细胞存活和增殖中的作用.
评估MM中PRMT1抑制的治疗潜力.

主要方法:

定制的CRISPR/Cas9屏幕针对DNA损伤反应基因.
用PRMT1抑制剂GSK3368715.1治疗MM细胞系的治疗方法
通过RPPA分析细胞存活率,氨酸甲基化水平 (ADMA,MMA),细胞周期进展,基因表达和蛋白质水平.

主要成果:

PRMT1被确定为MM细胞的关键生存依赖性.
治疗GSK3368715以剂量依赖的方式降低了MM细胞存活率.
抑制PRMT1导致ADMA减少,MMA增加,G0/G1细胞循环停止,并降低增殖和DNA损伤反应基因的调节.
RPPA证实了细胞周期和DDR相关蛋白的水平降低.

结论:

毫米细胞对PRMT1的生存非常依赖.
抑制PRMT1代表了对多发性骨髓瘤的有前途的治疗策略.
向PRMT1可以克服MM的化学抵抗和疾病复发.

关键词:

在CRISPR/Cas9屏幕上美国GSK336871515 多发性骨髓瘤是一种多发性骨髓瘤.在PRMT1中,

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Published on: August 7, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...